Shares jumped 6.1% to $33.50 after Vera Therapeutics posted second-quarter results that cleared a low bar while giving investors their first glimpse of life as a commercial drug company. The question now: whether early sales momentum and upcoming clinical data can justify a stock that still trades at barely half the average analyst target.
The Earnings Beat Barely Moves the Needle, but It Signals Discipline. Vera reported a net loss of $109.5 million, or -$1.52 per share, versus the -$1.60 consensus — a modest beat driven by lighter-than-expected spending during its first weeks selling a drug. Last quarter, the company missed estimates by 27%, so even a small beat resets the credibility clock . But Vera is still burning cash fast: operating cash outflows hit $206.8 million in the first half of 2026, nearly double the year-ago period .
A Half-Billion-Dollar Runway Buys Time, Not Certainty. The company ended June with $499.2 million in cash and marketable securities, plus up to $425 million available under a debt facility . That cushion matters because Vera priced its weekly injectable kidney-disease drug at $425,000 per year — a premium to rival Otsuka's Voyxact at $390,000 . Guggenheim projects only about $29 million in 2026 sales from roughly 1,050 new prescriptions , meaning revenue won't meaningfully offset losses this year.
The Real Stock-Mover Is a Data Readout Weeks Away. Vera has aligned with the FDA on an earlier analysis of its late-stage trial measuring kidney function, with results expected this quarter and a supplemental FDA filing targeted for Q4 2026 . The current approval rests on a surrogate measure — reduced protein in urine — not proof the drug actually slows kidney decline . Positive kidney-function data would unlock full approval and remove a key overhang; a miss could unravel the thesis entirely.
A Crowded Market Caps the Upside. Vera's drug now competes with five other approved therapies, including Novartis's Fabhalta and Travere's Filspari , and Vertex has a rival drug under FDA review with a November 30 decision date . Despite 14 analysts rating the stock a "Strong Buy" with an average target near $82 , Wedbush cut its target to $34 from $43 and maintains a neutral stance — notably just pennies above today's price. The gap between bulls and skeptics is unusually wide, and the Q3 data will likely settle the debate.